Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

27. oktober 2026 opdateret af: Boehringer Ingelheim

En dobbeltblind, randomiseret, placebokontrolleret forsøg, der evaluerer effektiviteten og sikkerheden af ​​nerandomilast over 26 uger hos patienter med systemiske autoimmune reumatiske sygdomme, der er forbundet med interstitielle lungesygdomme (SARD-ild)

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease.

Participants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

414

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Australien
    • New South Wales
      • Camperdown, Sydney, New South Wales, Australien, 2050
        • Royal Prince Alfred Hospital
      • Darlinghurst, New South Wales, Australien, 2010
        • St Vincent's Hospital Sydney
    • Queensland
      • Chermside, Queensland, Australien, 4032
        • The Prince Charles Hospital
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
        • Austin Hospital
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • Fiona Stanley Hospital
  • Det Forenede Kongerige
      • Antrim, Det Forenede Kongerige, BT41 2RL
        • Antrim Area Hospital
      • Bath, Det Forenede Kongerige, BA1 3NG
        • Royal United Hospital, Bath
      • Birmingham, Det Forenede Kongerige, B9 5SS
        • Heartlands Hospital
      • Leeds, Det Forenede Kongerige, LS7 4SA
        • Chapel Allerton Hospital
      • London, Det Forenede Kongerige, NW3 2QG
        • Royal Free Hospital
      • London, Det Forenede Kongerige, SW17 0QT
        • St George's Hospital
      • London, Det Forenede Kongerige, WC1E 6BT
        • University College Hospital
      • Londonderry, Det Forenede Kongerige, BT47 6SB
        • Altnagelvin Area Hospital
      • Luton, Det Forenede Kongerige, LU4 8RB
        • Luton & Dunstable University Hospital
      • Preston, Det Forenede Kongerige, PR2 9HT
        • NIHR Lancashire Clinical Research Facility
      • Sheffield, Det Forenede Kongerige, S5 7AU
        • Northern General Hospital
      • Truro, Det Forenede Kongerige, TR1 3LJ
        • Royal Cornwall Hospital
      • Westcliffe-on-Sea, Det Forenede Kongerige, SS0 0RY
        • Southend University Hospital
  • Forenede Stater
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35205
        • University of Alabama at Birmingham
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85259
        • Mayo Clinic-Arizona
    • California
      • Los Angeles, California, Forenede Stater, 90095
        • University of California Los Angeles
      • San Diego, California, Forenede Stater, 92108
        • Paradigm Clinical Research - San Diego
    • Colorado
      • Denver, Colorado, Forenede Stater, 80206
        • National Jewish Health
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06510
        • Yale University School of Medicine
    • Florida
      • Brandon, Florida, Forenede Stater, 33511
        • Meris Clinical Research-Brandon-69466
      • Miami, Florida, Forenede Stater, 33125
        • Miami VA Healthcare System
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30309
        • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
      • Augusta, Georgia, Forenede Stater, 30912
        • Augusta University
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University
      • Chicago, Illinois, Forenede Stater, 60637
        • The University of Chicago Medical Center
      • Evanston, Illinois, Forenede Stater, 60201
        • Northshore University Health System
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • University of Kansas Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • University of Minnesota
      • Rochester, Minnesota, Forenede Stater, 55902
        • Mayo Clinic, Rochester
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68198-1230
        • University of Nebraska Medical Center
    • New York
      • Great Neck, New York, Forenede Stater, 11021
        • Northwell Health
      • New York, New York, Forenede Stater, 10017
        • NYU Langone Health
      • New York, New York, Forenede Stater, 10032
        • New York Presbyterian Hospital -Columbia University
    • North Carolina
      • Salisbury, North Carolina, Forenede Stater, 28144
        • Onsite Clinical Solutions
      • Winston-Salem, North Carolina, Forenede Stater, 27103
        • Southeastern Research Center-Winston Salem-69289
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • Temple Lung Center
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • The University of Texas Health Science Center at Houston
      • San Antonio, Texas, Forenede Stater, 78229
        • University of Texas Health Science Center at San Antonio
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84108
        • University of Utah Health Sciences Center
    • West Virginia
      • Beckley, West Virginia, Forenede Stater, 25801
        • Rheumatology and Pulmonary Clinic
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • University of Wisconsin
  • Frankrig
      • Angers, Frankrig, 49933
        • HOP d'Angers
      • Bordeaux, Frankrig, 33076
        • HOP Pellegrin
      • Lille, Frankrig, 59037
        • Hôpital Claude Huriez
      • Paris, Frankrig, 75014
        • Hôpital Cochin
      • Paris, Frankrig, 75018
        • HOP Bichat
      • Rennes, Frankrig, 35203
        • HOP Sud
      • Strasbourg, Frankrig, 67091
        • HOP Civil
      • Toulouse, Frankrig, 31059
        • Hôpital Rangueil - CHU de Toulouse
  • Holland
      • Heerlen, Holland, 6419 PC
        • Zuyderland Medisch Centrum
      • Nieuwegein, Holland, 3435 CM
        • St. Antonius Ziekenhuis
      • Rotterdam, Holland, 3015
        • Erasmus Medisch Centrum-ROTTERDAM-50697
  • Italien
      • Brescia, Italien, 25123
        • ASST degli Spedali Civili di Brescia
      • Florence, Italien, 50134
        • A. O. Universitaria Careggi
      • Milan, Italien, 20132
        • Ospedale San Raffaele S.r.l.
      • Milan, Italien, 20122
        • Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico
      • Padova, Italien, 35128
        • Azienda Ospedaliera Universitaria di Padova
      • Pavia, Italien, 27100
        • Fondazione IRCCS Policlinico S. Matteo
      • Roma, Italien, 00161
        • AOU Policlinico Umberto I
  • Japan
      • Aichi, Toyoake, Japan, 470-1192
        • Fujita Health University Hospital
      • Fukuoka, Kitakyushu, Japan, 807-8556
        • Hospital of the University of Occupational and Environmental Health
      • Hiroshima, Hiroshima, Japan, 734-8551
        • Hiroshima University Hospital
      • Hokkaido, Sapporo, Japan, 060-8543
        • Sapporo Medical University Hospital
      • Hokkaido, Sapporo, Japan, 060-8648
        • Hokkaido University Hospital
      • Kagawa, Kita-gun, Japan, 761-0793
        • Kagawa University Hospital
      • Kanagawa, Kawasaki, Japan, 216-8511
        • St. Marianna University Hospital
      • Kanagawa, Sagamihara, Japan, 252-0375
        • Kitasato University Hospital
      • Kyoto, Kyoto, Japan, 606-8507
        • Kyoto University Hospital
      • Nagasaki, Nagasaki, Japan, 852-8501
        • Nagasaki University Hospital
      • Osaka, Takatsuki, Japan, 569-8686
        • Osaka Medical and Pharmaceutical University Hospital
      • Saitama, Iruma-gun, Japan, 350-0495
        • Saitama Medical University Hospital
      • Tokyo, Bunkyo-Ku, Japan, 113-8431
        • Juntendo University Hospital
      • Tokyo, Bunkyo-ku, Japan, 113-8603
        • Nippon Medical School Hospital
      • Tokyo, Shinjuku-ku, Japan, 160-8582
        • Keio University Hospital
  • Kina
      • Beijing, Kina, 100730
        • Peking Union Medical College Hospital
      • Beijing, Kina, 100020
        • Beijing Chao-Yang Hospital
      • Beijing, Kina, 100029
        • China-Japan Friendship Hospital
      • Chengdu, Kina, 610041
        • West China Hospital, Sichuan University
      • Chengdu, Kina, 610072
        • Sichuan Provincial People's Hospital
      • Guangzhou, Kina, 510080
        • Guangdong Provincial People's Hospital
      • Hangzhou, Kina, 310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine
      • Hangzhou, Kina, 310003
        • The First Affiliated Hospital, Zhejiang University
      • Luoyang, Kina, 471000
        • The First Affiliated Hospital of Henan University of Science and Technology
      • Macau, Kina, 999078
        • University Hospital_Macau University of Science and Technology
      • Nanchang, Kina, 330006
        • The First Affiliated Hospital of Nanchang University
      • Shanghai, Kina, 200040
        • Huashan Hospital, Fudan University
      • Tianjin, Kina, 30052
        • Tianjin Medical University General Hospital
      • Wuhan, Kina, 430030
        • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
      • Wuhan, Kina, 430022
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
      • Xiamen, Kina, 361003
        • First Affiliated Hospital of Xiamen University
      • Zhuzhou, Kina, 412007
        • Zhuzhou Central Hospital
  • Mexico
      • Chihuahua City, Mexico, 31020
        • Investigacion y Biomedicina de Chihuahua S.C.
      • Guadalajara, Mexico, 44160
        • Centro Integral en Reumatologia, SA. de CV.
      • Mexico City, Mexico, 14080
        • Inst Nac de Ciencias Medicas y Nutricion Salvador Zubiran
      • Mexico City, Mexico, 03650
        • Soltmed Smo
      • Mexico City, Mexico, 06700
        • CITER Centro de Investigación y Tratamiento de las Enfermedades Reumaticas SA de CV
      • Monterrey, Mexico, 64460
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • Mérida, Mexico, 97070
        • Medical Care & Research SA de CV
  • Norge
      • Nordbyhagen, Norge, 1478
        • Akershus Universitetssykehus HF
      • Skien, Norge, N-3710
        • Sykehuset Telemark HF, Avd. Skien
  • Puerto Rico
      • San Juan, Puerto Rico, 00917
        • GCM Medical Group, PSC
  • Schweiz
      • Aarau, Schweiz, CH-5001
        • Cantonal Hospital of Aarau
      • Basel, Schweiz, 4031
        • Universitätsspital Basel
      • Geneva, Schweiz, 1205
        • Hopitaux Universitaires de Geneve (HUG)
      • Neuchâtel, Schweiz, 2000
        • Neuchatel Hospital Network
      • Sankt Gallen, Schweiz, 9007
        • Kantonsspital St.Gallen
      • Zurich, Schweiz, 8091
        • University Hospital Zurich
  • Spanien
      • Barcelona, Spanien, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spanien, 08026
        • Hospital Santa Creu i Sant Pau
      • Bilbao, Spanien, 48013
        • Hospital de Basurto
      • Córdoba, Spanien, 14004
        • Hospital Universitario Reina Sofía
      • Huelva, Spanien, 21005
        • Hospital Juan Ramón Jimenez
      • L'Hospitalet de Llobregat, Spanien, 08907
        • Hospital Universitari de Bellvitge
      • Madrid, Spanien, 28040
        • Fundación Jiménez Díaz
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien, 28034
        • Hospital Universitario Ramon Y Cajal
      • Santiago de Compostela, Spanien, 15706
        • Hospital Clínico de Santiago
      • Seville, Spanien, 41009
        • Hospital Universitario Virgen De La Macarena
      • Seville, Spanien, 41013
        • Hospital Virgen del Rocio
      • Valencia, Spanien, 46017
        • Hospital Dr. Peset
      • Vigo, Spanien, 36312
        • Complejo Hospitalario Universitario de Vigo
  • Sydkorea
      • Seongnam, Sydkorea, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Sydkorea, 03080
        • Seoul National University Hospital
      • Seoul, Sydkorea, 04401
        • Soonchunhyang University Hospital Seoul
      • Seoul, Sydkorea, 02447
        • Kyung Hee University Hospital
  • Tyskland
      • Berlin, Tyskland, 10117
        • Charité - Universitätsmedizin Berlin
      • Berlin, Tyskland, 13125
        • Immanuel-Krankenhaus GmbH
      • Bonn, Tyskland, 53127
        • Universitätsklinikum Bonn AöR
      • Braunschweig, Tyskland, 38126
        • Städtisches Klinikum Braunschweig gGmbH
      • Bremen, Tyskland, 28325
        • Gesundheit Nord gGmbH | Klinikverbund Bremen
      • Cologne, Tyskland, 51149
        • Krankenhaus Porz am Rhein gGmbH
      • Düsseldorf, Tyskland, 40225
        • Universitätsklinikum Düsseldorf
      • Essen, Tyskland, 45239
        • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
      • Freiburg im Breisgau, Tyskland, 79106
        • Universitätsklinikum Freiburg
      • Gommern, Tyskland, 39245
        • Helios Fachklinik Vogelsang-Gommern GmbH
      • Hanover, Tyskland, 30625
        • Medizinische Hochschule Hannover
      • Herne, Tyskland, 44649
        • St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
      • Kirchheim unter Teck, Tyskland, 73230
        • medius Kliniken gGmbH
      • Konstanz, Tyskland, 78464
        • Klinikum Konstanz
      • Lübeck, Tyskland, 23538
        • Universitätsklinikum Schleswig-Holstein, Campus Lübeck
      • Minden, Tyskland, 32429
        • Johannes Wesling Klinikum Minden
      • München, Tyskland, 80336
        • Klinikum der Universität München AÖR
      • Regensburg, Tyskland, 93049
        • Krankenhaus Barmherzige Brüder Regensburg
  • Østrig
      • Krems, Østrig, 3500
        • Krems University Hospital
      • Wels, Østrig, 4600
        • Klinikum Wels - Grieskirchen GmbH

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant has systemic autoimmune rheumatic diseases associated interstitial lung diseases (SARD-ILD), defined as

    • Diagnosis by a rheumatologist (or equally qualified medical physician) with at least 1 of the following SARDs: Rheumatoid arthritis (RA), systemic sclerosis (SSc) (participants must be anticentromere auto-antibody negative), idiopathic inflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissue disease (MCTD) (participants must be anti-U1-ribonucleoprotein particle (RNP) auto-antibody positive)
    • Presence of fibrotic interstitial lung disease (ILD) on high-resolution computed tomography (HRCT), defined as presence of reticular abnormality with traction bronchiectasis with or without honeycombing (HC), with disease extent >10% on HRCT performed within 12 months of Visit 1 or, if historical scan is not available, on baseline HRCT taken prior to Visit 2, as confirmed by central review

  • No lung function improvement and no clinically significant ILD improvement as a treatment response to immunosuppressant (IS) therapy according to both criteria:

    • No improvement in absolute forced vital capacity (FVC) % predicted >5% within the 15 months prior to Visit 1, as measured by 2 spirometry assessments that must be ≥3 months apart. (Note: 1: In the case of multiple PFTs over the 15 months prior to screening, exceptional values of absolute change in FVC % predicted >5% are acceptable if the overall trend of FVC % predicted is declining or stable; note 2: Visit 1 spirometry may be used to fulfill the inclusion criterion if there is only 1 spirometry reading in the 15 months prior to Visit 1)
    • No clinically significant improvement in ILD based on clinician's judgement (including symptoms, imaging/HRCT, or other assessments as considered relevant and documented by the Investigator)

  • FVC ≥45% of predicted normal at Visit 1

  • Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for haemoglobin (Hb) within 3 months prior to or at Visit 1

  • Participants must be on stable treatment with any IS agent for ≥6 months (or ≥3 months for participants with IIM-ILD) prior to visit 2, with the following specifications:

    • If using prednisone, participants must be on stable dose for ≥4 weeks prior to Visit 2
    • If using rituximab, participants must have completed their first cycle >6 months prior to Visit 2

  • If using nintedanib, participants must be on a stable dose for ≥12 weeks prior to Visit 2

  • In the opinion of the Investigator, no change in background standard of care (SoC) treatment with immunosuppressant (IS), immunomodulator (IM), or nintedanib is planned

  • Further inclusion criteria apply

Exclusion Criteria:

  • Organising pneumonia as predominant pattern in the HRCT
  • Prebronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) <0.7 at Visit 1
  • Acute ILD exacerbation within 3 months prior to Visit 1 and/or during the screening period, based on Investigator judgement
  • Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period
  • Any suicidal behaviour in the past 2 years
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 3 months or at Visit 1, and/or at Visit 2
  • Use of any of the following medications: cyclophosphamide within 6 months of Visit 1, pirfenidone within 8 weeks of Visit 1
  • Further exclusion criteria apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Nerandomilast

Participants with SARD-ILDs will receive nerandomilast.
Medicin: Nerandomilast

Nerandomilast

Andre navne:
  • Jascayd®
Placebo komparator: Placebo

Participants with SARD-ILDs will receive placebo.
Medicin: Placebo matching nerandomilast

Placebo matching nerandomilast

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26
Tidsramme: At baseline and at Week 26

QILD will be assessed via quantitative high-resolution computed tomography (qHRCT). QILD are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung. QHC is a measure of HC within the lung. QILD is the sum of QLF, QGGO, and QHC.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD [%] is the QILD volume [mL] as a percent of the total lung volume.

A higher QILD percentage or volume indicates a higher extent of disease.
At baseline and at Week 26

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Absolut ændring fra baseline i vaskulært volumen [%] på HRCT i uge 26
Tidsramme: Ved baseline og i uge 26
Ved baseline og i uge 26
Absolut ændring fra baseline i supplerende iltbrug over hele forsøget for iltbrugere ved baseline
Tidsramme: Ved baseline og i uge 52
Ved baseline og i uge 52
Tid til første supplerende iltbrug under forsøget for ikke-brugere af ilt ved baseline
Tidsramme: Op til uge 52
Op til uge 52
Forekomst af infektionsrelaterede bivirkninger (AES) fra basislinjen i løbet af forsøgets varighed
Tidsramme: Op til 1 år
Op til 1 år
Absolute change from baseline in quantitative lung fibrosis (QLF) score [%] on HRCT at Week 26
Tidsramme: At baseline and at Week 26

QLF will be assessed via qHRCT. QLF are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD [%] is the QILD volume [mL] as a percent of the total lung volume.

A higher QILD percentage or volume indicates a higher extent of disease.
At baseline and at Week 26
Absolute change from baseline in quantitative ground glass opacity (QGGO) score [%] on HRCT at Week 26
Tidsramme: At baseline and at Week 26

QGGO will be assessed via qHRCT. QGGO are quantitative measures of different radiological patterns associated with lung fibrosis. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung.

Quantification of HRCT scans will be performed centrally via a machine learning algorithm.

A higher QGGO percentage or volume indicates a higher extent of disease.
At baseline and at Week 26
Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 26
Tidsramme: At baseline and at Week 26

FVC will be assessed using standardised spirometry equipment which will be provided centrally with supplies of precalibrated disposable flow sensors. Spirometry will be conducted with the participant in a seated position. It is preferable that the same trained individual (i.e. PFT specialist or pulmonologist) performs the PFTs for a given participant. The best of 3 efforts will be defined as the highest FVC obtained on any of three blows meeting the 2019 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (with a maximum of eight attempts). Predicted normal values will be calculated according to global lung function initiative (GLI).
At baseline and at Week 26

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Boehringer Ingelheim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. september 2025

Primær færdiggørelse (Anslået)

15. april 2027

Studieafslutning (Anslået)

28. april 2027

Datoer for studieregistrering

Først indsendt

28. januar 2025

Først indsendt, der opfyldte QC-kriterier

28. januar 2025

Først opslået (Faktiske)

4. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 1305-0046
  • U1111-1305-5857 (Registry Identifier: WHO International Clinical Trials Registry Platform (ICTRP))
  • 2024-512849-17-00 (Registry Identifier: CTIS (EU))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Once the criteria in section "time frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD-delingstidsramme

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

IPD-delingsadgangskriterier

For study documents -upon signing of a "Document Sharing Agreement". For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner